Medical equipment maker Senseonics Q3 revenue rises

Senseonics Holdings

05/11/2025 21:46

Overview

Senseonics Q3 revenue rose 90% yr/yr to $8.1 mln, driven by U.S. patient growth

Company plans transition of CGM commercial responsibility back from Ascensia

Senseonics executed a 1-for-20 reverse stock split, listing to move to Nasdaq

Outlook

Senseonics expects full-year 2025 global net revenue to be approximately $35 mln

Company anticipates EU launch of Eversense 365 in H1 2026

Gross margins expected to be between 35% and 40% for full-year 2025

Result Drivers

U.S. PATIENT GROWTH - 160% increase in U.S. new patient starts drove revenue growth

DTC MARKETING - Expanded direct-to-consumer marketing generated record new patient leads

COMMERCIAL TRANSITION - Planning to transition CGM commercial responsibility from Ascensia back to Senseonics

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.43
Q3 Net Income
-$19.53 mln
Q3 Gross Profit
$3.47 mln
Q3 Operating Income
-$19.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Senseonics Holdings Inc is $24.00, about 72.1% above its November 4 closing price of $6.69

Press Release: ID:nGNX3Zyqh4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)